Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: Results of CHILI CU soon

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 761-769

  Mengden, Thomas ^a   Hübner, Reinhold ^b   Bramlage, Peter ^c  

^a KERCKHOFF HEART CENTER   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c Institut für Kardiovaskuläre Pharmakologie und Epidemiologie   (Germany)

Author keywords

Ambulatory blood pressure; Normalization; Office blood pressure; Response

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; HYDROCHLOROTHIAZIDE; POTASSIUM; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 84861684683     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S26887     Document Type: Article

References (14)

1. Uen S, Un I, Fimmers R, Vetter H, Mengden T. Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension. Dtsch Med Wochenschr. 2007;132(3):81-86.
2. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig. 2009;29(5):293-304.
3. Bönner G. Antihypertensive efficacy and tolerability of candesartanhydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press. 2008; 17(Suppl 2):22-30.
4. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-1892.
5. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156-161.
6. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407-2415.
7. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. November 24, 2008;168(21):2340-2346.
8. Bramlage P, Schonrock E, Odoj P, Wolf WP, Funken C. Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ. MMW Fortschr Med. 2008;149(Suppl 4):172-181.
9. Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison of the antihypertensive effects of the candesartan 8 mg hydrochlorothiazide 12.5 mg combination vs the valsartan 80 mg hydrochlorothiazide 12.5 mg combination in patients with essential hypertension resistant to monotherapy [abstract no. P2.367]. J Hypertens. 2004;22(Suppl 2): S254-S255.
10. Mengden T, Binswanger B, Weisser B, Vetter W. An evaluation of selfmeasured blood pressure in a study with a calcium-channel antagonist versus a beta-blocker. Am J Hypertens. 1992;5(3):154-160.
11. Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ. 2010;340:c1104.
12. Luders S, Franz IW, Hilgers KF, et al. Twenty-four hour ambulatory blood pressure monitoring. Dtsch Med Wochenschr. 2005;130(46): 2664-2668.
13. Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens. Sep 1997;11(Suppl 2):S85-S89.
14. Bönner G, Landers B, Bramlage P. Candesartan cilexitil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag. 2011;7:85-95.